top of page

ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

Search

Parenting after a ROS1+ Cancer Diagnosis

Dec 29, 2019
3 min

Parenting after a ROS1+ Cancer Diagnosis

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Janet Freeman-Daily

Nov 8, 2019
1 min

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Travel Tips

Aug 13, 2019
2 min

Travel Tips

Fundraising Update

Aug 5, 2019
1 min

Fundraising Update

The Few…The Proud…The ROS1ders!

Jul 31, 2019
3 min

The Few…The Proud…The ROS1ders!

untitled image

Janet Freeman-Daily

May 15, 2019
1 min

The ROS1ders Interview Dr. Ross Camidge

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Janet Freeman-Daily

May 4, 2019
1 min

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Donating ROS1 Tissue

Marisa Wittebort

Apr 30, 2019
2 min

Donating ROS1 Tissue

ROS1 by the Numbers

Apr 17, 2019
2 min

ROS1 by the Numbers

ROS1 News From Europe

Bärbel Söhlke

Apr 15, 2019
2 min

ROS1 News From Europe

Addario to Merge with Lung Cancer Alliance

Mar 31, 2019
1 min

Addario to Merge with Lung Cancer Alliance

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Janet Freeman-Daily

Feb 18, 2019
1 min

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Advocating for ROS1

Janet Freeman-Daily

Jan 29, 2019
1 min

Advocating for ROS1

Thinking about a “drug vacation” from crizotinib? Read this first!

Janet Freeman-Daily

Jan 16, 2019
3 min

Thinking about a “drug vacation” from crizotinib? Read this first!

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 30, 2018
1 min

Crizotinib approved for ROS1 in Australia

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 13, 2018
1 min

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 4, 2018
1 min

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Janet Freeman-Daily

Sep 10, 2018
6 min

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Detection of ROS1 rearrangement in lung cancer remains “complex”

Janet Freeman-Daily

Aug 31, 2018
1 min

Detection of ROS1 rearrangement in lung cancer remains “complex”

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 26, 2018
1 min

Crizotinib may be effective again after chemo

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Janet Freeman-Daily

Jun 14, 2018
1 min

TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP

Pfizer new lung cancer drug is successful for funding.

Janet Freeman-Daily

May 31, 2018
1 min

Pfizer new lung cancer drug is successful for funding.

The Unnecessary Cruelty of Clinical Trials

Apr 6, 2018
5 min

The Unnecessary Cruelty of Clinical Trials

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

Jan 4, 2017
4 min

Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)

bottom of page